Year: 2021

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd...

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition

GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition

GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study...

Foresight Diagnostics’ PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas

PhasED-Seq ctDNA detection results were highly correlated with CT imagingPhasED-Seq ctDNA detection may predict response to targeted agents as early...

Universe Pharmaceuticals INC Announces Strategic Alliance with Kitanihon Pharmaceutical Co., Ltd. to Address the Market Demand for Kampo Medicine and High-end Traditional Chinese Medicine

Ji’an, Jiangxi, China, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...

Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers

Partnership pairs Akoya’s spatial phenotyping solutions and PathAI’s AI-based algorithms to elucidate spatial biomarker signatures for biopharma partners Collaboration Combining...

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

Published Study Titled, “Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma”CRANBURY, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Rafael...

error: Content is protected !!